Eupraxia Pharmaceuticals reports Q1 results
May 05, 2022 5:54 PM ETEupraxia Pharmaceuticals Inc. (EPRXF), EPRX:CABy: Meghavi Singh, SA News Editor
- Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q1 net loss of $3.8 million for the three months ended March 31, 2022, versus $8.9 million for the quarter ended March 31, 2021.
- The Company had a cash and short-term investments balance of $25.9 million as at March 31, 2022.
- Management believes it has sufficient resources to fund the Company through to the fourth quarter of 2023.